摘要 |
PCT No. PCT/SE93/00425 Sec. 371 Date Feb. 1, 1994 Sec. 102(e) Date Feb. 1, 1994 PCT Filed May 14, 1993 PCT Pub. No. WO93/23071 PCT Pub. Date Nov. 25, 1993.The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus. the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth. |